A Strategic Pivot: Alphabet’s Verily Shuts Down Its Medical Devices Division to Focus on AI
Do Son 
Alphabet’s life sciences and health-tech subsidiary, Verily, has announced the closure of its medical devices division and the layoff of associated staff. The number of individuals affected remains undisclosed, but the decision underscores Alphabet’s ongoing strategic pivot—reallocating resources toward artificial intelligence and data infrastructure initiatives.
Verily, once heralded as one of Google’s most promising “moonshot” ventures, has advanced cutting-edge efforts in smart diabetes solutions, robotic surgery technologies, and other pioneering medical applications.
However, internal communications reveal that Verily has made the difficult decision to discontinue investment in medical device manufacturing and will no longer offer technical support in this domain.
In a statement, CEO Stephen Gillett acknowledged that, while the medical devices business was never a primary revenue generator for Alphabet, its innovations provided substantial value to medical research and clinical care. Notable achievements include the Dexcom G7 continuous glucose monitoring system, developed in partnership with Dexcom, and the Stargazer VNRC drug-screening platform, which has supported clinical testing for over 7,800 patients. These accomplishments continue to resonate within the med-tech landscape.
Since Alphabet’s large-scale restructuring in 2023—during which 12,000 employees were laid off—the company has been increasingly channeling resources into AI, cloud computing, and data-driven precision medicine. The shuttering of Verily’s device arm appears to be a further manifestation of that strategic realignment.
Gillett emphasized that Verily will refocus on its core mission: precision health powered by AI and data analytics, advancing medical research and clinical applications. This signals a transformation of Verily from a hardware manufacturer to a platform provider of medical data and AI services.
As the global healthcare industry increasingly embraces digital transformation—incorporating AI-assisted diagnostics, integrated health records, and personalized wellness management—the shift positions Verily, and by extension Alphabet, to play a more strategically significant role in the emerging health-technology ecosystem.
Related Posts:
- Alphabet Q1 2025: Revenue Surges, Gemini 2.5 Launched
- Alphabet to Acquire Cybersecurity Powerhouse Wiz for $23 Billion
- Alphabet Soars in Q2: AI Fuels 14% Revenue Jump to $96.4B, Google Cloud Profits Skyrocket
- LINE Data Breach Expands: Investigation Uncovers More Compromised Data
Support Our Threat Intelligence
If you find our CVE report and cybersecurity news helpful, consider supporting our work.
Buy Me a Coffee
PayPal
